Laurie A. VanderVeen
机构：Gilead Sciences (United States)
发表论文 52 篇 · 总被引 1176 次 · h-index 14
代表论文
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study (2024 · The Lancet HIV · 被引 47)
- Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years (2025 · The Journal of Infectious Diseases · 被引 33)
- Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model (2023 · Journal of Clinical Investigation · 被引 16)
- Lenacapavir treatment–emergent HIV-1 capsid resistance mutations are frequently associated with replication defects (2026 · Science Translational Medicine · 被引 12)
- Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy (2024 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 9)
- Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab (2025 · The Journal of Infectious Diseases · 被引 8)